Drugs / AP31969
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07449390 | Apr → May 2026 | — | Acesion Pharma | Completed | No outcome recorded |
| Phase 1 | NCT06066099 | Oct 2023 → Mar 2025 | — | Acesion Pharma | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07267949 | Oct 2025 → Nov 2026 expected | atrial fibrillation | Acesion Pharma | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AP31969 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07267949 ↗ |
| Route | Oral | “Oral tablets” NCT06066099 ↗ |